Repositioning Candidate Details
| Candidate ID: | R1008 |
| Source ID: | DB06421 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Declopramide |
| Synonyms: | Declopramide |
| Molecular Formula: | C13H20ClN3O |
| SMILES: | CCN(CC)CCNC(=O)C1=CC=C(N)C(Cl)=C1 |
| Structure: |
|
| DrugBank Description: | -- |
| CAS Number: | 891-60-1 |
| Molecular Weight: | 269.77 |
| DrugBank Indication: | Investigated for use/treatment in colorectal cancer and inflammatory bowel disease. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | Declopramide is a member of the N-substituted benzamide class of DNA repair inhibitors. There are two possible mechanisms of action of declopramide, with one involving (nuclear localizing factor kappaB) NFkB and the other involving the activation of the caspase cascade via the mitochondrial pathway, both of which lead to cell death (apoptosis). Declopramide may also increase the susceptibility of cancer cells to traditional radiation and/or chemotherapy treatment. It is proposed that G2/M cell cycle block is induced by pathways other than the protein 53 (p53) pathway. |
| Targets: | DNA; DNA topoisomerase 2-alpha; DNA topoisomerase 2-beta |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S13 | Anti-apoptosis | hepatocyte apoptosis; hepatic autophagy; apoptosis | Pan-caspase inhibitor | Emricasan | Details |
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|